Aspirin dramatically increased FOXD3 concentrations in the nuclei of cancer cells and effectively promoted FOXD3 interaction with OLA1P2 promoter regions, providing convincing evidence that FOXD3 is a new aspirin target that could function in the control of lncRNA transcription. The gene discussed is FOXD3; the disease is cancer.